Movement Alert｜BIOCYTOGEN-B Rises 5.71% in Regular Trading, H1 Profit Expected to Surge Over 4x Ahead of Earnings Release

Market Focus08-20

On August 20, BIOCYTOGEN-B rose 5.71% in regular trading, trading at 64.15 HKD/share, with turnover of approximately 28.15 million HKD.

On the news front, the company previously issued an H1 earnings preview projecting net profit attributable to shareholders of 236 million to 246 million yuan, representing a year-over-year increase of 392% to 413%. Revenue is expected to reach 936 million to 946 million yuan, up 51% to 52% year-over-year. The board is scheduled to convene on August 27 to review interim results and consider an interim dividend.

The rally appears to be a technical recovery from a 7.83% decline on August 17, combined with renewed buying interest ahead of the formal earnings release. Strong H1 performance follows a robust Q1 in which revenue surged 74% to 433 million yuan and net profit reached 104 million yuan, marking a turnaround from a year-ago loss. Institutional positioning has also been supportive, with E Fund Management raising its stake to 10.0% through multiple purchases in recent months.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1175832593?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-20 09:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1175832593","market":"hk","top_or_hot":-1,"title":"Movement Alert｜BIOCYTOGEN-B Rises 5.71% in Regular Trading, H1 Profit Expected to Surge Over 4x Ahead of Earnings Release","media":"Market Focus","content":"<p><p>On August 20, BIOCYTOGEN-B rose 5.71% in regular trading, trading at 64.15 HKD/share, with turnover of approximately 28.15 million HKD.</p><p>On the news front, the company previously issued an H1 earnings preview projecting net profit attributable to shareholders of 236 million to 246 million yuan, representing a year-over-year increase of 392% to 413%. Revenue is expected to reach 936 million to 946 million yuan, up 51% to 52% year-over-year. The board is scheduled to convene on August 27 to review interim results and consider an interim dividend.</p><p>The rally appears to be a technical recovery from a 7.83% decline on August 17, combined with renewed buying interest ahead of the formal earnings release. Strong H1 performance follows a robust Q1 in which revenue surged 74% to 433 million yuan and net profit reached 104 million yuan, marking a turnaround from a year-ago loss. Institutional positioning has also been supportive, with E Fund Management raising its stake to 10.0% through multiple purchases in recent months.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜BIOCYTOGEN-B Rises 5.71% in Regular Trading, H1 Profit Expected to Surge Over 4x Ahead of Earnings Release</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜BIOCYTOGEN-B Rises 5.71% in Regular Trading, H1 Profit Expected to Surge Over 4x Ahead of Earnings Release\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-20 09:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 20, BIOCYTOGEN-B rose 5.71% in regular trading, trading at 64.15 HKD/share, with turnover of approximately 28.15 million HKD.</p><p>On the news front, the company previously issued an H1 earnings preview projecting net profit attributable to shareholders of 236 million to 246 million yuan, representing a year-over-year increase of 392% to 413%. Revenue is expected to reach 936 million to 946 million yuan, up 51% to 52% year-over-year. The board is scheduled to convene on August 27 to review interim results and consider an interim dividend.</p><p>The rally appears to be a technical recovery from a 7.83% decline on August 17, combined with renewed buying interest ahead of the formal earnings release. Strong H1 performance follows a robust Q1 in which revenue surged 74% to 433 million yuan and net profit reached 104 million yuan, marking a turnaround from a year-ago loss. Institutional positioning has also been supportive, with E Fund Management raising its stake to 10.0% through multiple purchases in recent months.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02315","symbol_name":"百奥赛图-B","start_time":0,"source_url":"","article_id":"1175832593","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1175832593","pubTimestamp":1787190572,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 20, BIOCYTOGEN-B rose 5.71% in regular trading, trading at 64.15 HKD/share, with turnover of approximately 28.15 million HKD.On the news front, the company previously issued an H1 earnings...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02315":"百奥赛图-B"},"translate_title":"走势警报|BIOCYTOGEN-B 常规交易上涨 5.71%，财报发布前上半年利润预计飙升 4 倍以上","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02315":1},"content_text":"On August 20, BIOCYTOGEN-B rose 5.71% in regular trading, trading at 64.15 HKD/share, with turnover of approximately 28.15 million HKD.On the news front, the company previously issued an H1 earnings preview projecting net profit attributable to shareholders of 236 million to 246 million yuan, representing a year-over-year increase of 392% to 413%. Revenue is expected to reach 936 million to 946 million yuan, up 51% to 52% year-over-year. The board is scheduled to convene on August 27 to review interim results and consider an interim dividend.The rally appears to be a technical recovery from a 7.83% decline on August 17, combined with renewed buying interest ahead of the formal earnings release. Strong H1 performance follows a robust Q1 in which revenue surged 74% to 433 million yuan and net profit reached 104 million yuan, marking a turnaround from a year-ago loss. Institutional positioning has also been supportive, with E Fund Management raising its stake to 10.0% through multiple purchases in recent months.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.48.0","shortVersion":"4.48.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1175832593","isCrawlerRequest":true}